interesting, that the comments have been that the Isradipine study/results would be icing on the cake. But seems the cake (sales/revenue) as a result of approved product launches is no where to be seen. All the discussion is switched to Isradipine. What about the Lannett partnership and related launch? IMO, something isn't right and the company's silence is telling.
Market Data 
Markets 
AI
